These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 28581362)

  • 1. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.
    Han L; Shen WJ; Bittner S; Kraemer FB; Azhar S
    Future Cardiol; 2017 May; 13(3):279-296. PubMed ID: 28581362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of PPARβ/δ in the management of metabolic syndrome and its associated cardiovascular complications.
    Benetti E; Patel NS; Collino M
    Endocr Metab Immune Disord Drug Targets; 2011 Dec; 11(4):273-84. PubMed ID: 21696362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of peroxisome proliferator-activated receptor isoforms alpha, beta/delta, and gamma mediate distinct facets of hypertrophic transformation of adult cardiac myocytes.
    Pellieux C; Montessuit C; Papageorgiou I; Lerch R
    Pflugers Arch; 2007 Dec; 455(3):443-54. PubMed ID: 17643263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPAR dual agonists: are they opening Pandora's Box?
    Balakumar P; Rose M; Ganti SS; Krishan P; Singh M
    Pharmacol Res; 2007 Aug; 56(2):91-8. PubMed ID: 17428674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel approach to treat insulin resistance, type 2 diabetes, and the metabolic syndrome: simultaneous activation of PPARalpha, PPARgamma, and PPARdelta.
    Evans JL; Lin JJ; Goldfine ID
    Curr Diabetes Rev; 2005 Aug; 1(3):299-307. PubMed ID: 18220606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases.
    Monsalve FA; Pyarasani RD; Delgado-Lopez F; Moore-Carrasco R
    Mediators Inflamm; 2013; 2013():549627. PubMed ID: 23781121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Insights on the Role of PPAR-β/δ in Neuroinflammation and Neurodegeneration, and Its Potential Target for Therapy.
    Strosznajder AK; Wójtowicz S; Jeżyna MJ; Sun GY; Strosznajder JB
    Neuromolecular Med; 2021 Mar; 23(1):86-98. PubMed ID: 33210212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
    Qiu YY; Zhang J; Zeng FY; Zhu YZ
    Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PPAR family and its relationship to metabolic syndrome].
    Zhang XY; Chen LH; Guan YF
    Sheng Li Ke Xue Jin Zhan; 2005 Jan; 36(1):6-12. PubMed ID: 15881336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PPAR-gamma receptors, new therapeutic target in metabolic and cardiovascular diseases].
    Scheen AJ; Paquot N
    Rev Med Liege; 2005 Feb; 60(2):89-95. PubMed ID: 15819371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational PPAR-gamma agonists for the treatment of Type 2 diabetes.
    Savkur RS; Miller AR
    Expert Opin Investig Drugs; 2006 Jul; 15(7):763-78. PubMed ID: 16787140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptor β/δ and γ agonists differentially affect prostaglandin E2 and cytokine synthesis and nutrient transporter expression in porcine trophoblast cells during implantation.
    Blitek A; Szymanska M
    Theriogenology; 2020 Aug; 152():36-46. PubMed ID: 32361305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPAR agonists for the treatment of neuroinflammatory diseases.
    Titus C; Hoque MT; Bendayan R
    Trends Pharmacol Sci; 2024 Jan; 45(1):9-23. PubMed ID: 38065777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensitivities of the vascular K(ATP) channel to various PPAR activators.
    Wang Y; Yu L; Cui N; Jin X; Zhu D; Jiang C
    Biochem Pharmacol; 2013 May; 85(10):1495-503. PubMed ID: 23500542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
    Tenenbaum A; Motro M; Fisman EZ
    Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.
    Grygiel-Górniak B
    Nutr J; 2014 Feb; 13():17. PubMed ID: 24524207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.